Overview: Cryptococcus Antibody (Crypto Ab) TestIntroduction: The Cryptococcus Antibody Test detects antibodies to Cryptococcus, indicating fungal infection causing headaches or lung issues. Following 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in mycology for patients with suspected cryptococcal infections, particularly in immunocompromised individuals.
Other Names: Cryptococcus Ab Assay, Fungal Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting mycology standards for diagnostic accuracy.
Historical Milestone: Cryptococcus antibody testing began in the 1970s with fungal infection research. Immunoassays emerged in the 1980s, and by the 2000s, high-sensitivity assays improved diagnostic accuracy.
Purpose: Diagnoses cryptococcal infection, guides antifungal therapy, and monitors antibody levels in patients with headaches or lung issues.
Test Parameters: 1. Cryptococcus Antibody
Pretest Condition: No fasting required. Collect serum or cerebrospinal fluid (CSF) at any time. Report symptoms like headaches, fever, or cough, and list immunocompromising conditions or medications.
Specimen: 2-5 mL serum (SST) or 1-2 mL CSF (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document headaches, lung issues, or immunocompromised states (e.g., HIV, organ transplant). Include current medications, especially antifungals or immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antifungal therapy.
Procedural Considerations: Uses an immunoassay to measure Cryptococcus antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Immunosuppression or early infection may cause false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm cryptococcal infection, prompting antifungal therapy. Negative results may require antigen or PCR testing.
Specialist Consultation: Consult an infectious disease specialist for result interpretation. A neurologist or pulmonologist referral is advised for neurological or lung involvement.
Additional Supporting Tests: Cryptococcus antigen test, CSF analysis, or chest imaging to confirm infection or assess complications.
Test Limitations: False negatives may occur in early or immunocompromised cases. Results require clinical correlation with antigen testing.
References: IDSA Cryptococcus Guidelines, 2023; Clinical Infectious Diseases, Perfect JR, 2022.
